Significant adverse event: epistaxis · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids probably leads to higher significant adverse event: epistaxis compared with placebo (moderate certainty).
1 finding from 1 review
Disease‐specific health‐related quality of life Short Form 12 (SF‐12v2) (range 0 to 800) · adults and children > 12 with non‐allergic rhinitis
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · adults and children > 12 with non‐allergic rhinitis
It is very uncertain whether intranasal corticosteroids changes objective measurement of airflow: peak flow rate (expiratory) compared with placebo (very low certainty).
1 finding from 1 review
Other adverse events · adults and children > 12 with non‐allergic rhinitis
Intranasal corticosteroids showed no clear difference in other adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Death at 1 month (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 1 month (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death at 3 to 4 months (adults) · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids leads to lower death at 3 to 4 months (adults) compared with no such treatment (high certainty).
1 finding from 1 review
Death in hospital; children · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids showed no clear difference in death in hospital; children compared with no such treatment (moderate certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with Pneumocystis jiroveci pneumonia and HIV infection
Adjunctive corticosteroids probably leads to lower need for mechanical ventilation at 1 month compared with no such treatment (moderate certainty).
1 finding from 1 review
Improvement in vertigo frequency · Ménière’s disease
Intratympanic corticosteroids showed no clear difference in improvement in vertigo frequency compared with placebo/no treatment (low certainty).
2 findings from 1 review
Change in vertigo (global score) · Ménière’s disease
1 finding from 1 review
Change in vertigo frequency · Ménière’s disease
3 findings from 1 review
no estimate extracted
3 studies · 472 participants
Low
no estimate extracted
1 study · 20 participants
Very low
no estimate extracted
1 study · 18 participants
Very low
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
Intratympanic corticosteroids may leads to higher proportion of patients whose hearing is improved compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in final hearing threshold determined by PTA (a lower value represents… compared with no treatment or versus placebo (low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistent tympanic membrane perforation · sudden sensorineural hearing loss
1 finding from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found